CSI Market
Sign In | Register

Astria Therapeutics Inc (ATXS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ATXS Annual Cash Flow →
From Astria Therapeutics Inc through Sep 30 2024, changes in Sep 30 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-98.40
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue16.54
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation12.50
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Services Received In Non Monetary Exchange-
Non Cash Portion Of Acquired Research And Development-
Gain Loss On Warrant Inherited-
Increase Decrease In Right Of Use Asset Operating-0.89
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-17.24
Increase (Decrease) in Accounts Payable-3.18
Increase (Decrease) in Accrued Liabilities3.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-13.11
Other Working Capital0.00
Other Noncash Income (Expense)0.17
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.80
Discontinued operations0.00
Net Cash flow from Operating Activities-102.37
Investing Activities
Capital Expenditures-0.59
Sale of Capital Items0.00
Short-term Investments Proceeds139.42
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities138.83
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Stock Options Exercised And Warrants Exercised-
Payment Of Deferred Initial Public Offering Costs-
Proceeds From Issuance Of At Market Offering-
Proceeds From Exercise Of Stock Options And Warrant Financial Activities0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-102.96
Total Cash Flow36.46
4 historic quarters locked

Sign in to unlock the full Astria Therapeutics Inc cash flow history.

Sign In Create Free Account

About Astria Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-25-110377

Figures are derived from filed reports and may be restated. Historical data is subject to revision.